SLS - Company ID 0001390478
The table below shows SELLAS Life Sciences Group, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A |
SELLAS Life Sciences Group, Inc. reported annual revenue of $0.00 for fiscal year 2023. That is down 100.0% from $1.00M in fiscal 2022. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $4.12M |
| $2.87M |
| $3.00M |
| $2.86M |
| $2.97M |
| $2.44M |
| Operating income | -$9.25M | -$7.08M | -$6.87M | -$6.06M | -$7.33M | -$7.62M |
| Income tax | - | - | - | - | - | - |
| Net income | -$8.41M | -$6.79M | -$6.60M | -$5.81M | -$7.11M | -$7.47M |
| EPS (diluted) | -$0.05 | -$0.06 | -$0.07 | -$0.07 | -$0.10 | -$0.13 |